0001317757-11-000020.txt : 20110628
0001317757-11-000020.hdr.sgml : 20110628
20110628162008
ACCESSION NUMBER: 0001317757-11-000020
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20110624
FILED AS OF DATE: 20110628
DATE AS OF CHANGE: 20110628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: English Edward C
CENTRAL INDEX KEY: 0001302600
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-10865
FILM NUMBER: 11935991
MAIL ADDRESS:
STREET 1: C/O PRAECIS PHARMACEUTICALS INCORPORATED
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC.
CENTRAL INDEX KEY: 0000792977
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 042742593
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 6174983300
MAIL ADDRESS:
STREET 1: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: ADVANCED MAGNETICS INC
DATE OF NAME CHANGE: 19920703
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0203
3
2011-06-24
0
0000792977
AMAG PHARMACEUTICALS INC.
AMAG
0001302600
English Edward C
C/O AMAG PHARMACEUTICALS, INC.
100 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
VP, Controller, Interim CFO
Common Stock
88
D
Stock Options
65.14
2017-05-22
Common Stock
7500
D
Stock Options
59
2017-10-01
Common Stock
600
D
Stock Options
47.08
2018-02-26
Common Stock
6000
D
Stock Options
36.6
2018-07-01
Common Stock
1500
D
Restricted Stock Units
2012-08-19
Common Stock
1000
D
Stock Options
27
2019-03-04
Common Stock
7000
D
Stock Options
38.39
2020-01-04
Common Stock
1750
D
Stock Options
35.13
2020-03-02
Common Stock
4000
D
Restricted Stock Units
2014-03-02
Common Stock
876
D
Restricted Stock Units
2013-11-15
Common Stock
5000
D
Stock Options
17.44
2020-12-17
Common Stock
2000
D
These shares were acquired by the reporting person pursuant to the Company's 2006 Employee Stock Purchase Plan. The purchase price for the shares was $48.99, 85% of the closing price of the Company's common stock on November 30, 2007.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vested in four equal installments on May 22, 2008, May 22, 2009. May 22, 2010 and May 22, 2011.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vests in four equal installments. Installments one, two and three vested on October 1, 2008, October 1, 2009 and October 1, 2010, respectively. The fourth installment will vest on October 1, 2011.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one, two and three vested on February 26, 2009, February 26, 2010 and February 26, 2011, respectively. The fourth installment will vest on February 26, 2012.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on July 1, 2009 and July 1, 2010. The third and fourth installments will vest on July 1, 2011 and July 1, 2012.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on August 19, 2010, 25% on August 19, 2011 and the remaining 25% on August 19, 2012.
Each restricted stock unit represents a contingent right to receive one share of common stock.
Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on March 4, 2010 and March 4, 2011. Installments three and four will vest on March 4, 2012 and March 4, 2013.
Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on January 4, 2011. Installments two, three and four will vest on January 4, 2012, January 4, 2013 and January 4, 2014, respectively.
Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on March 2, 2011. Installments two, three and four will vest on March 2, 2012, March 2, 2013 and March 2, 2014, respectively.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on March 2, 2011. Installments two, three and four will vest on March 2, 2012, March 2, 2013 and March 2, 2014, respectively.
Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on November 15, 2011, 25% on November 15, 2012 and the remaining 25% on November 15, 2013.
Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments on December 17, 2011, December 17, 2012, December 17, 2013 and December 17, 2014.
Joseph L. Farmer, attorney-in-fact
2011-06-28
EX-99
2
powerofattorney.txt
POWER OF ATTORNEY
POWER OF ATTORNEY
For Executing Forms 3, 4 and 5
Know all by these present,that the undersigned hereby
constitutes and appoints each of Brian J.G. Pereira and
Joseph Farmer, signing singly, his true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned,in the
undersigneds capacity as an officer and/or director of
AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5
(including any amendments thereto) in accordance with Section
16(a) of the Securities Exchange Act of 1934,
as amended and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
the execution of any such Forms 3, 4 and 5 and the timely filing
of such forms with the United States Securities and Exchange
Commission and any other authority; and
(3) take any other action of any type whatsoever in connection
with the foregoing which,in the opinion of such attorney-in-fact
may be of benefit to,in the best interest of,or legally required
by,the undersigned,it being understood that the documents
executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact
may approve in his discretion.
The undersigned hereby grants to each such attorney-in-fact full
power and authority to do and perform all and every act and thing
whatsoever requisite, necessary and proper to be done in the
exercise of any of the rights and powers herein granted,as fully
to all intents and purposes as the undersigned might or could do
if personally present,with full power of substitution or revocation
hereby ratifying and confirming all that such attorney-in-fact, or
his substitute or substitutes, shall lawfully do or cause to be done
by virtue of this Power of Attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing
attorneys-in-fact, in serving in such capacity at the request of
the undersigned, are not assuming, nor is the Company assuming,
any of the undersigneds responsibilities to comply with Section 16
of the Securities Exchange Act of 1934, as amended.
This Power of Attorney replaces in their entirety any and all
prior powers of attorney executed by the undersigned with respect
to the subject matters set forth herein, including any powers of
attorney previously filed with the Securities and Exchange
Commission. This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required to file
Forms 3, 4 and 5 with respect to the undersigneds holdings of and
transactions in securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed this 27th day of June 2011.
Signed: /s/ Edward C. English
Please Print: Edward C. Engish